The historical rank and industry rank for Viracta Therapeutics's Days Inventory or its related term are showing as below:
VIRX's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.875 * Ranked among companies with meaningful Days Inventory only.
Viracta Therapeutics's Days Inventory
stayed the same
from Sep. 2023 (0.00) to Sep. 2024 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Viracta Therapeutics (OTCPK:VIRX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Viracta Therapeutics's Inventory Turnover for the
three
months ended in Sep. 2024 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Viracta Therapeutics's Inventory to Revenue for the
three
months ended in Sep. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Viracta Therapeutics Days Inventory Related Terms
Viracta Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Viracta Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VIRX vs TSOI, CYTOF, TRVN: Days Inventory Comparison
For the Biotechnology subindustry, Viracta Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viracta Therapeutics (VIRX) has a Days Inventory of 0.00 as of Sep. 2024. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Days Inventory too high?
Viracta Therapeutics' current Days Inventory is 0.00.
How does Viracta Therapeutics' Days Inventory compare to TSOI and CYTOF?
Viracta Therapeutics' Days Inventory of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Inventory is 183.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Viracta Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viracta Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Days Inventory is 0.00 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIRX has been successfully added to your 